January 4, 2018 / 5:44 PM / 6 months ago

BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide

Jan 4 (Reuters) - Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY

* RHYTHM PHARMACEUTICALS - SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY

* RHYTHM PHARMACEUTICALS - FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY

* RHYTHM PHARMACEUTICALS - CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below